ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "C-reactive protein (CRP)"

  • Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting

    Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study

    Talia Igel1,2, Aaron Garza Romero2, Virginia Pike3, Stuart Katz4, Binita Shah5, Irina Dektiarev4, Svetlana Krasnokutsky Samuels6 and Michael H. Pillinger7, 1Monash University School of Medicine, Melbourne, Australia, 2Medicine/Rheumatology, NYU School of Medicine, New York, NY, 3Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 4Medicine/Cardiology, NYU School of Medicine, New York, NY, 5NYU School of Medicine, Division of Cardiology, New York, NY, 6Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
  • Abstract Number: 378 • 2016 ACR/ARHP Annual Meeting

    Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series

    Annalouise O'Connor1, Sara Le Brun-Blashka2, Kirti Salunkhe2, Jyh-Lurn Chang2 and John Troup2, 1R&D, Metagenics, Inc., Gig Harbor, WA, 2Metagenics, Inc., Gig Harbor, WA

    Background/Purpose:  The inflammatory response has an initiation phase and a resolution phase. Ideally, inflammation leads to complete resolution that enables tissue healing and a return…
  • Abstract Number: 506 • 2016 ACR/ARHP Annual Meeting

    The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis

    Arthur Kavanaugh1, Boulos Haraoui2, Prashanth Sunkureddi3, Benjamin Wolfe4, Li Wang4, Jessica Suboticki4 and Edward Keystone5, 1University of California San Diego, La Jolla, CA, 2University of Montreal, Montreal, QC, Canada, 3University of Texas Medical Branch, Galveston, TX, 4AbbVie Inc., North Chicago, IL, 5Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: For patients (pts) with rheumatoid arthritis (RA), quantification of radiographic progression, through measures such as modified total Sharp score (mTSS), is not routinely captured…
  • Abstract Number: 560 • 2016 ACR/ARHP Annual Meeting

    There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration

    Inger Marie J. Hansen1,2,3, Rikke Asmussen4, Steen Antonsen5 and Amir Emamifar6, 1Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, 2University of Southern Denmark, 5000 Odense, Denmark, 3DANBIO, Glostrup, Denmark, 4Dep. of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark, 5Biochemestry, OUH, Svendborg Hospital, 5700 Svendborg, Denmark, 6Rheumatology, OUH, Svendborg Hospital, 5700 Svendborg, Denmark

    Background/Purpose: The threshold for reporting of C-reactive protein (CRP) differs from laboratory to laboratory. Moreover, CRP values are affected by the intra individual biological variability.[1]…
  • Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting

    Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting

    Irene Lazarus1, Salahuddin Kazi2, Alok Dwivedi3, Christopher Dodoo4 and Kanchan Pema5, 1Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, 2Rheumatology, UT Southwestern Medical Center, Dallas, TX, 3Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, 4Texas Tech University Health Sciences Center, El Paso, TX, 5Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX

    Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
  • Abstract Number: 342 • 2015 ACR/ARHP Annual Meeting

    The Effect of Erosive Status on Systemic Inflammatory Biomarkers in Hand Osteoarthritis

    Alexander Mathiessen1, Nina Østerås2, Tore K. Kvien3, Hilde Berner Hammer4 and Ida K. Haugen5, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology,, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5P.O. Box 23, Diakonhjemmet Hospital, Vinderen, Norway

    Background/Purpose : It is debated whether erosive hand osteoarthritis (OA) is a separate inflammatory subset of hand OA, or just a severe form of the same…
  • Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting

    Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis

    Xin Wang1, Arthur Kavanaugh2, Désirée van der Heijde3, Maxime Dougados4, Stefan Florentinus1, Yihan Li1, Iain Sainsbury1 and Josef S. Smolen5, 1AbbVie Inc., North Chicago, IL, 2University of California San Diego, La Jolla, CA, 3Leiden University Medical Center, Leiden, Netherlands, 4René Descartes University and Hôpital Cochin, Paris, France, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…
  • Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting

    Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

    Matthew A. Brown1, Paul A. Bird2, Philip C. Robinson3, Philip J. Mease4, Filip van Den Bosch5, Christine Surian6, Zirke Wiid6, Heather Jones7, Annette Szumski8 and Lisa Marshall7, 1Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 2University of New South Wales, Sydney, Australia, 3University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, 4Rheumatology Research, Swedish Medical Center, Seattle, WA, 5Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 6Pfizer Australia, Sydney, Australia, 7Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 8Department of Biostatistics, Pfizer, Collegeville, PA

    Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
  • Abstract Number: 1527 • 2015 ACR/ARHP Annual Meeting

    Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis

    James S. Andrews1, Elizabeth R. Wahl2, Gabriela Schmajuk3, Edward H. Yelin4 and Patricia P. Katz5, 1Rheumatology, University of California San Francisco, San Francisco, CA, 2Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, 3San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 4University of California, San Francisco, San Francisco, CA, 5Rheumatology, UCSF, SF, CA

    Background/Purpose: Frailty has been defined as “an excess vulnerability to stressors, with reduced ability to maintain or regain homeostasis after a destabilizing event” 1.  Frailty…
  • Abstract Number: 2681 • 2015 ACR/ARHP Annual Meeting

    Physical Function, Sleep, Depression but Not CRP Level Is Associated with Fatigue in Patients with Established Rheumatoid Arthritis

    Yong Gil Hwang1, Juan (June) Feng2, Heather Eng2, Jason Lyons2, Anthony Fabio3 and Larry W. Moreland4, 1Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 3Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by inflammation of the joints and fatigue. Although many studies have identified risk factors for RA-associated fatigue, few studies…
  • Abstract Number: 2429 • 2014 ACR/ARHP Annual Meeting

    Seasonal Changes May Influence Activity of Rheumatoid Arthritis

    Ryuji Nagamine, Bone and Joint Center, Sugioka Memorial Hospital, Fukuoka, Japan

    Background/Purpose: RA activity during the year was assessed to investigate whether seasonal changes influenced parameters of RA activity. Methods: This study was performed in Fukuoka,…
  • Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting

    A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE

    Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany

    Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
  • Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting

    Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients

    Brigitte Michelsen1, Andreas P. Diamantopoulos2, Arthur Kavanaugh3 and Glenn Haugeberg1,4, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 3University of California San Diego, La Jolla, CA, 4Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway

    Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…
  • Abstract Number: 1580 • 2014 ACR/ARHP Annual Meeting

    Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort

    Soumya M. Reddy1, Jose U. Scher1, Christopher Swearingen2 and Yusuf Yazici1, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR

    Background/Purpose: Routine care cohorts can provide data about patient phenotypes, treatment choices and responses in the 'real world'. Studying the true impact of psoriatic arthritis…
  • Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting

    Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of  Anti-Ro Associated Congenital Heart Block

    Amit Saxena1, Peter M. Izmirly2, Sung Won Han3, Andrew Markham4, Robert M. Clancy5 and Jill P. Buyon5, 1Rheumatology, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Department of Population Health, New York University School of Medicine, New York, NY, 4Medicine, New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB).  Identification of maternal…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology